TET2 and nonpapillary renal cell carcinoma: Similarly, a recent study discovered that high-dose Vit-C inhibits the development of ccRCC cells in vitro by activating TET2 [194], implying that TET2 may be a potential therapeutic target for the clinical treatment of ccRCC patients.